Erschienen in:
01.02.2007 | Phase II Studies
Arsenic trioxide in patients with hepatocellular carcinoma: a phase II trial
verfasst von:
Chia-Chi Lin, Chiun Hsu, Chih-Hung Hsu, Wei-Ling Hsu, Ann-Lii Cheng, Chih-Hsin Yang
Erschienen in:
Investigational New Drugs
|
Ausgabe 1/2007
Einloggen, um Zugang zu erhalten
Summary
Background: Arsenic trioxide induces growth inhibition and apoptosis in human hepatocellular carcinoma (HCC) cell lines. A phase II trial was conducted to evaluate the efficacy and toxicity of single-agent arsenic trioxide in patients with HCC.
Methods: Inclusion criteria included advanced HCC patients to whom no standard palliative treatment can be offered, good organ function and liver function reserve. Patients received arsenic trioxide 0.16–0.24 mg/kg per day for 5–6 days per week for 3–4 weeks, followed by one-week rest. Tumor response was assessed every 2 cycles. Primary endpoint was the percentage of patients with 6-month disease stabilization.
Results: Twenty-nine patients (median age, 59) with locally advanced or metastatic HCC received a total of 61 cycles (median, 2; range, 1–6). One patient had partial response. Three patients had disease stabilization for at least six months. The 6-month tumor stabilization rate was 14% (95% CI, 1–27). The median overall survival was 4.8 months (95% CI, 1.4–8.2) and one-year survival was 30%.
Conclusion: Single-agent arsenic trioxide using this dose schedule is not active against advanced HCC.